October 2, 2014 | The cancer and immune-inflammatory treatments developer VBL Therapeutics raised $40 million at a company value of $120 million in a revived NASDAQ IPO. Just this August, the company had raised $65 million at a company value of $222 million, but after a principle US investor couldn’t come through with the money promised, the company was forced to cancel its offering and delist. In this, the latest offering, the company sold over 6 million shares at $6 per share, but by the end of the day the share price had fallen to $5.85. Deutsche Bank Services was the book-running manager for the IPO, together with co-managers JMP Securities and Oppenheimer. VBL Therapeutics was founded in 2000 and is based in Tel Aviv.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments